Popular Articles
Teeth Whitening

MacroGenics And Lilly Achieve Targeted Patient Enrollment In PROTEGE, A Global Phase 2/3 Clinical Trial Of Teplizumab In Type 1 Diabetes
MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the treatment of individuals with recent-onset type 1 diabetes.
generic viagra online
New NHS Focus On Audiology Brings Faster Hearing Aid Treatment
A determined effort by Audiology teams across the country has led to 99% of people receiving hearing aids or other appropriate treatment within the government"s 18-week target. Figures for February 2009, just released by the Department of Health, show that the situation has been improving every month since April 2008. The improvements have come about as a result of re-instating frozen posts combined with a determined effort by Audiology teams to work in more flexible and creative ways.
plastic surgery before after
News of the day
Radiotherapy Link To Breast Cancer And Heart Disease Found
Scientists have found a way to identify breast cancer patients at risk of heart disease after radiotherapy, according to a report published yesterday.
Public Health

Confirmed Link Between Chronic Infection And Immune-System Protein

The reason deadly infections like human immunodeficiency virus (HIV) and hepatitis C never go away is because these viruses disarm the body"s defense system. Researchers at the University of Alabama at Birmingham (UAB) have discovered that a key immunity protein must be present for this defense system to have a chance against chronic infection. Research up to now has tried but failed to decipher the cross-talk between "killer T-cells" and "helper T-cells" in the fight against viruses. The new UAB study finds this cross-talk can only happen in the presence of interleukin-21, a powerful immune system protein. If interleukin-21 is missing for whatever reason, then the immune system"s anti-viral efforts fail, said Allan Zajac, Ph.D., an associate professor in UAB"s Department of Microbiology and lead author on the study. The findings are published in the journal Science through its Science Express service. "Adding interleukin-21 back in stimulates the immune response and controls the infection," Zajac said. "We demonstrate that the loss of this protein prevents the control of the infection and diminishes the function of the killer T-cells, specifically CD8 T-cells." The study mice were treated for lymphocytic choriomeningitis, a viral infection of the membranes surrounding the brain and spinal cord. Measurements were taken for two types of T-cells, CD4 and CD8 T-cells, before and after the mice were treated with interleukin-21. "Interleukin-21 served as the key messenger between the T-cells, whereas before we didn"t know exactly how the two types of cells communicated with each other," Zajac said. The CD4 T-cells help the immune system do its job by boosting CD8 T-cells" ability to fight and kill viruses. Co-authors on the study include John Yi and Ming Du, Ph.D., both of UAB"s Department of Microbiology. Research funds came from the National Institutes of Health. Troy Goodman University of Alabama at Birmingham


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):